Amesergide acts as a [[binding selectivity|selective]] [[receptor antagonist|antagonist]] of the [[serotonin receptor|serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2B receptor|5-HT<sub>2B</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]]s (K<sub>i</sub> = 1.96–15.1&nbsp;nM).<ref name="pmid1731051" /><ref name="pmid8632342" /> It is also an antagonist of the serotonin [[5-HT7 receptor|5-HT<sub>7</sub> receptor]] with relatively lower [[affinity (pharmacology)|affinity]] (K<sub>i</sub> = 78.0&nbsp;nM).<ref name="pmid15032609">{{cite journal | vauthors = Leopoldo M | title = Serotonin(7) receptors (5-HT(7)Rs) and their ligands | journal = Curr. Med. Chem. | volume = 11 | issue = 5 | pages = 629–61 | year = 2004 | pmid = 15032609 | doi = | url = }}</ref> The drug is a [[potency (pharmacology)|potent]] antagonist of the [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic receptor]] in addition to the [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]s via its major [[active metabolite]] 4-hydroxyamesergide (K<sub>i</sub> = 13&nbsp;nM).<ref name="pmid8027933" /><ref name="HertzmanFeltner1997">{{cite book|author1=Marc Hertzman|author2=Douglas E. Feltner|title=The Handbook of Psychopharmacology Trials: An Overview of Scientific, Political, and Ethical Concerns|url=https://books.google.com/books?id=Mn9lrAQ_nxUC&pg=PA390|date=June 1997|publisher=NYU Press|isbn=978-0-8147-3532-9|pages=390–}}</ref> This profile of activity is similar to that of the so-called [[noradrenergic and specific serotonergic antidepressant]] (NaSSA) [[mirtazapine]] (Remeron).<ref name="pmid9017762">{{cite journal | vauthors = Stimmel GL, Dopheide JA, Stahl SM | title = Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects | journal = Pharmacotherapy | volume = 17 | issue = 1 | pages = 10–21 | year = 1997 | pmid = 9017762 | doi = | url = }}</ref>
